LC
VRDN icon

Lindbrook Capital’s Viridian Therapeutics VRDN Stock Holding History

Lindbrook Capital’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-187
Closed -$3.27K – 2843
2024
Q1 		$3.27K Hold
187
– – ﹤0.01% 2071
2023
Q4 		$4.07K Sell
187
-81
-30% -$1.28K ﹤0.01% 1995
2023
Q3 		$4.11K Buy
268
+112
+72% +$2.14K ﹤0.01% 1849
2023
Q2 		$3.71K Hold
156
– – ﹤0.01% 1931
2023
Q1 		$3.97K Buy
+156
New +$5K ﹤0.01% 1948
2022
Q3 		– Sell
-1,006
Closed -$12K – 2927
2022
Q2 		$12K Buy
+1,006
New +$13.5K ﹤0.01% 1198

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Lindbrook Capital's VRDN Position: Q2 2024 in Review

Lindbrook Capital sold out of Viridian Therapeutics (VRDN) in Q2 2024, closing a stake of 187 shares — an estimated $3.27K sold.

Lindbrook Capital first reported a position in VRDN in Q2 2022 and held it in 6 quarters. The position peaked at $12K in Q2 2022. 138 funds tracked by Wall St. Rank hold VRDN as of Q2 2024.

  • Lindbrook Capital reported no remaining Viridian Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Lindbrook Capital sold 187 Viridian Therapeutics shares in Q2 2024, an estimated $3.27K.
  • Lindbrook Capital first reported a position in Viridian Therapeutics in Q2 2022 and held it in 6 quarters.
  • Lindbrook Capital's Viridian Therapeutics position peaked at $12K in Q2 2022.
  • 138 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2024.

Based on Lindbrook Capital's 13F filing for Q2 2024, filed 31 Jul 2024.